Literature DB >> 10223232

Ethnic differences in the behavior of hepatocellular carcinoma.

P L Chin1, D Z Chu, K G Clarke, T Odom-Maryon, Y Yen, L D Wagman.   

Abstract

BACKGROUND: The purpose of this study was to examine the clinical presentation, prognostic factors, and survival rates of patients with hepatocellular carcinoma (HCC) and to examine differences between Asian and non-Asian patients with HCC.
METHODS: A review of the clinical characteristics and laboratory evaluations for 76 patients in two different broad ethnic groups (Asians [Group 1] and non-Asians [Group 2]) who underwent treatment for HCC from 1977-1995 was performed. Chi-square and Cox regression analyses were performed to assess factor interaction and association with survival.
RESULTS: A total of 24 patients in Group 1 and 52 patients in Group 2 were reviewed. Of the clinical variables examined, a higher rate of a history of hepatitis B positivity was observed in Group 1 compared with Group 2 (32% vs. 6%; P=0.001). Among the 76 patients with HCC, a 1-year survival estimate of 41.4% was found. There was a borderline significant difference in survival between Group 1 and Group 2 with a 1-year survival estimate of 29.5% versus 46.9%, respectively (P=0.08). Better overall survival was found in patients who had tumors that were resectable (P=0.0001), had an alpha-fetoprotein level <10 ng/mL (P=0.02), or were a younger age at the time of diagnosis (P=0.01). There was a trend for Asian race (P=0.08) to be associated with poorer survival. When these risk factors were entered into a multivariate analysis, tumor resectability and non-Asian race were most predictive of improved survival (model P value = 0.007). When controlling for the multiple variables most often reported to be associated with HCC, Asians had a significantly lower survival than non-Asians (P<0.01).
CONCLUSIONS: In this study it appears that the outcome for Asian patients with hepatoma is worse than for non-Asian patients, even when controlling for factors commonly associated with HCC. Biologic or social factors that are not appreciated currently may be involved in Asian patients with HCC, contributing to a poorer clinical outcome.

Entities:  

Mesh:

Year:  1999        PMID: 10223232

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

1.  Hepatitis B and alcohol affect survival of hepatocellular carcinoma patients.

Authors:  Linda-L Wong; Whitney-M Limm; Naoky Tsai; Richard Severino
Journal:  World J Gastroenterol       Date:  2005-06-21       Impact factor: 5.742

2.  Hepatitis B and hepatitis C prevalence and treatment referral among Asian Americans undergoing community-based hepatitis screening.

Authors:  Jessica P Hwang; Mahfam Mohseni; Beverly J Gor; Sijin Wen; Heather Guerrero; John M Vierling
Journal:  Am J Public Health       Date:  2010-02-10       Impact factor: 9.308

3.  Prognostic determinants for survival after resection/ablation of a large hepatocellular carcinoma.

Authors:  Keh M Ng; Tristan D Yan; Deborah Black; Francis C K Chu; David L Morris
Journal:  HPB (Oxford)       Date:  2009-06       Impact factor: 3.647

4.  Association of transarterial chemoembolization with survival in patients with unresectable hepatocellular carcinoma.

Authors:  Peng Wang; Lili Sheng; Guoxiang Wang; Heping Wang; Xinyu Huang; Xiaoxing Yan; Xiaohua Yang; Renguang Pei
Journal:  Mol Clin Oncol       Date:  2014-01-07

5.  Clinical presentation of hepatocellular carcinoma (HCC) in Asian-Americans versus non-Asian-Americans.

Authors:  Philip Y Wong; Victor Xia; David K Imagawa; John Hoefs; Ke-Qin Hu
Journal:  J Immigr Minor Health       Date:  2011-10

Review 6.  Value of quality of life analysis in liver cancer: A clinician's perspective.

Authors:  Leung Li; Winnie Yeo
Journal:  World J Hepatol       Date:  2017-07-18

7.  Prognostic values of EORTC QLQ-C30 and QLQ-HCC18 index-scores in patients with hepatocellular carcinoma - clinical application of health-related quality-of-life data.

Authors:  Leung Li; Frankie Kf Mo; Stephen L Chan; Edwin P Hui; Nelson Sl Tang; Jane Koh; Linda Ks Leung; Annette Ny Poon; Joyce Hui; Cheuk M Chu; Kit F Lee; Brigette By Ma; Paul Bs Lai; Anthony Tc Chan; Simon Ch Yu; Winnie Yeo
Journal:  BMC Cancer       Date:  2017-01-04       Impact factor: 4.430

8.  Survival and hepatitis status among Asian Americans with hepatocellular carcinoma treated without liver transplantation.

Authors:  Jessica P Hwang; Manal M Hassan
Journal:  BMC Cancer       Date:  2009-02-04       Impact factor: 4.430

9.  Survival differences by race/ethnicity and treatment for localized hepatocellular carcinoma within the United States.

Authors:  Robert J Wong; Douglas A Corley
Journal:  Dig Dis Sci       Date:  2009-01-01       Impact factor: 3.199

10.  Ambovex(®) as a novel immunological modulator drug for the treatment of hepatocellular carcinoma (HCC) in the liver: a Phase II clinical trial.

Authors:  Hosny Salama; Hassan Ahmad; Ismail Elchagea; Abdel Rahman Zekri; Eman Medhat; Abeer Bahnassy; Michael Lange; Mohammed Rabbat; Andrew N de la Torre; Pravin Punamiya
Journal:  J Hepatocell Carcinoma       Date:  2015-06-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.